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Summary
 
A population of human T cells expressing an invariant V
 
a
 
24J
 
a
 
Q T cell antigen receptor
(TCR) 
 
a
 
 chain and high levels of CD161 (NKR-P1A) appears to play an immunoregulatory
role through production of both T helper (Th) type 1 and Th2 cytokines. Unlike other
CD161
 
1
 
 T cells, the major histocompatibility complex–like nonpolymorphic CD1d molecule
is the target for the TCR expressed by these T cells (V
 
a
 
24
 
invt
 
 T cells) and by the homologous
murine NK1 (NKR-P1C)
 
1
 
 T cell population. In this report, CD161 was shown to act as a
specific costimulatory molecule for TCR-mediated proliferation and cytokine secretion by
V
 
a
 
24
 
invt
 
 T cells. However, in contrast to results in the mouse, ligation of CD161 in the ab-
sence of TCR stimulation did not result in V
 
a
 
24
 
invt
 
 T cell activation, and costimulation
through CD161 did not cause polarization of the cytokine secretion pattern. CD161 mono-
clonal antibodies specifically inhibited V
 
a
 
24
 
invt
 
 T cell proliferation and cytokine secretion in
response to CD1d
 
1
 
 target cells, demonstrating a physiological accessory molecule function for
CD161. However, CD1d-restricted target cell lysis by activated V
 
a
 
24
 
invt
 
 T cells, which in-
volved a granule-mediated exocytotic mechanism, was CD161-independent. In further con-
trast to the mouse, the signaling pathway involved in V
 
a
 
24
 
invt
 
 T cell costimulation through
CD161 did not appear to involve stable association with tyrosine kinase p56
 
Lck
 
. These results
demonstrate a role for CD161 as a novel costimulatory molecule for TCR-mediated recogni-
tion of CD1d by human V
 
a
 
24
 
invt
 
 T cells.
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cell subsets which express CD161 (NKR-P1) are
found in humans and mice. In rodents there are three
NKR-P1 molecules, NKR-P1A, -B, and -C, which are
“NK locus”–encoded C-type lectins (1–4). Murine NK1
(NKR-P1C)
 
1
 
 T cells are either CD4
 
1
 
 or double negative
(DN)
 
1
 
 and constitutively express a range of additional
markers, such as Ly-49C and B220, which are not found
on conventional T cells (5–10). They also express a highly
restricted TCR repertoire consisting of an invariant
V
 
a
 
14J
 
a
 
281 
 
a
 
 chain in association with a restricted reper-
toire of V
 
b
 
 genes (7, 10–12). Genetic and reconstitution
studies demonstrated that NK1
 
1
 
 T cells are positively se-
lected by and recognize the MHC-unlinked 
 
b
 
2-microglo-
bulin–associated protein, CD1d (5, 6, 11, 13). Of human T
cell populations expressing the single known human NKR-P1
molecule, NKR-P1A (CD161), the subset that is analogous
to murine NK1
 
1
 
 T cells expresses an invariant V
 
a
 
24J
 
a
 
Q
TCR 
 
a
 
 chain paired predominantly with V
 
b
 
11 (14–20).
These human T cells, referred to here as V
 
a
 
24
 
invt
 
 T cells,
have been shown to specifically recognize CD1d (19).
TCR-mediated stimulation of human V
 
a
 
24
 
invt 
 
T cells
results in simultaneous production of large amounts of both
IL-4 and IFN-
 
g
 
, and hence they have been described as
Th0 cells (18–20). Similarly, murine NK1
 
1
 
 T cells can
produce large amounts of cytokines, notably IL-4, early in
immune responses (9, 21), and a role for NK1
 
1
 
 T cells in
promoting Th2 responses has been proposed (22). How-
ever, the murine NK1
 
1
 
 T cell population is clearly not es-
 
1
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a
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a
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T
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sential for all Th2 responses, since 
 
b
 
2-microglobulin–defi-
cient mice, which lack detectable NK1
 
1
 
 as well as most
CD8
 
1
 
 T cell populations, can still mount such responses
(23, 24). CD1d knockout mice, which similarly lack NK1
 
1
 
T cells, are also able to generate model Th2 responses, such
as nonspecific production of IgE (25–27). Murine NK1
 
1
 
 T
cells have also been shown to have NK-like cytotoxic ac-
tivity (8, 9, 12, 28). This NK-like activity is induced by IL-
12 (29) and appears to play a role in IL-12–mediated tumor
rejection, a Th1-like cell-mediated response (30). Al-
though the precise functions of human V
 
a
 
24
 
invt
 
 T cells re-
main to be defined, quantitative and qualitative defects in
these T cells or the corresponding murine population are
predictive of progression in certain human and murine au-
toimmune conditions (28, 31–35).
It has been established that NK locus–encoded C-type
lectins can mediate NK cell activation, and that rodent
NK1, but not human CD161, acts as an autonomous NK
cell stimulatory structure (3, 4, 36–38). Direct stimulation
of murine NK1
 
1
 
 T cells through NK1 rather than the
TCR results in a cytokine switch to IFN-
 
g
 
 (13, 39, 40),
suggesting that precisely how these cells are activated may
contribute to determining the composition of the immune
response. In this study, the role of the human NK1 homo-
logue CD161 and other candidate accessory molecules in
regulation of human DN V
 
a
 
24
 
invt
 
 T cell responses to
CD1d was assessed. The results demonstrated that CD161
functions as a costimulatory receptor for CD1d recognition
by V
 
a
 
24
 
invt
 
 T cells. However, in contrast to murine NK1
 
1
 
T cells, ligation of human CD161 on V
 
a
 
24
 
invt
 
 T cells did
not directly activate cytokine secretion, and CD161 co-
stimulation did not result in the selective production of
IFN-
 
g
 
. Our results identify CD161 expressed by V
 
a
 
24
 
invt
 
T cells as a costimulatory molecule for this unique T cell
population.
 
Materials and Methods
 
T Cell Clones and Cell Lines.
 
V
 
a
 
24
 
invt
 
 T cell clones were de-
rived and phenotypic analysis was performed as described (17,
19). In brief, a panel of DN V
 
a
 
24
 
1
 
V
 
b
 
11
 
1
 
 human peripheral
blood T cell clones was established by sequential negative mag-
netic bead (Dynal, Inc., Lake Success, NY) and positive FACS
 
Ò
 
sorting of human peripheral blood T cells, followed by stimula-
tion with PHA-P (Difco Laboratories Inc., Detroit, MI) and IL-2
(1.5 nM, equivalent to 
 
z
 
70 IU/ml; Ajinomoto, Yokohama, Ja-
pan) in the presence of irradiated (5,000 rads) peripheral blood
mononuclear cells. V
 
a
 
24
 
invt
 
 T cell clones were then established
by limiting dilution. CD4
 
1
 
 
 
V
 
a
 
24
 
invt
 
 TCR
 
2
 
 V
 
a
 
24
 
1
 
V
 
b
 
11
 
1
 
 
 
con-
trol T cells were established in a similar manner. Human CD1d-
transfected Chinese hamster ovary (CHO) cells and human HLA-
A, -B negative C1R B cells (41) were generated as described (19).
The murine V
 
a
 
14
 
invt
 
 TCR
 
1
 
 CD1d-specific T-T hybridoma
DN32.D3 (7) was provided by Dr. A. Bendelac (Princeton Uni-
versity, Princeton, NJ).
 
Antibodies.
 
Antibodies used were anti-V
 
a
 
24 (C15B2) and
anti-V
 
b
 
11 (C21D2), both provided by Dr. A. Lanzavecchia (In-
stitute for Immunology, Basel, Switzerland); anti-TCR 
 
ab
 
(BMA031; gift of Dr. R.G. Kurrle, Boehringwerke, Marburg,
Germany); anti-CD3 (SPV-T3b [provided by Dr. H. Spits,
Netherlands Cancer Center, Amsterdam, Netherlands] and
OKT3 [American Type Culture Collection, Rockville, MD]);
anti-CD4 (OKT4; American Type Culture Collection); anti-
CD8
 
a
 
 (OKT8; American Type Culture Collection); anti-CD8
 
b
 
(2ST8-5H7; provided by Dr. E. Reinherz, Dana-Farber Cancer
Institute, Boston, MA); anti-CD28 (9.3 [gift of Dr. J. Hansen,
Hutchinson Cancer Center, Seattle, WA] and CD28.2 [Phar-
Mingen, San Diego, CA]); anti-CD69 (FN50; PharMingen); anti-
CD94 mAb (DX-22 [gift of Dr. L. Lanier, DNAX, Palo Alto,
CA], HP-3D9 [PharMingen], HP-3B1 [Coulter Corp., Miami,
FL], and IgA NKH3 [provided by Drs. M. Robertson, Indiana
University Medical Center, Indianapolis, IN, and J. Ritz, Dana-
Farber Cancer Institute, Boston, MA]); anti-CD161 (DX-1 and
DX12 [also provided by Dr. Lanier], HP-3G10 [provided by Dr.
M. Lopez-Botet, Hospital de la Princesa, Madrid, Spain], and
191.B8 [gift of Dr. A. Poggi, Instituto Nazionale per la Ricerca
sul Cancro, Genoa, Italy]); anti-p40 (NKTA255; provided by Dr.
A. Poggi); p38 (C1.7; Coulter Corp.), Fifth Leukocyte Work-
shop, NK Section, mAb against killer inhibitory receptors p58
(GL183, EB6, CH-L, and HP-3E4) and p70 (DX-9; provided by
Dr. Lanier); anti-MHC class I (W6/32; American Type Culture
Collection), anti-CD1b (4A7.6.5, IgG2a; gift of Dr. D. Olive, In-
stitut Nationale de la Santé et de la Recherche Médicale,
Marseilles, France), and isotype control mAbs (P3, IgG1; MPC-
11, IgG2b; American Type Culture Collection); rat anti–murine
NK1.1 (PK136; PharMingen); and normal mouse and rat sera.
p56Lck was detected with a mixture of antibodies (#42 rabbit se-
rum [provided by Drs. B. Krise and J. Rose, Yale University,
New Haven, CT] and 3A5 mAb [Santa Cruz Biotechnology,
Inc., Santa Cruz, CA]). Multiple independent CD1d-specific
mAbs were raised using CD1d–IgG fusion protein as immunogen
(reference 19, and S. Porcelli and S. Balk, unpublished). CD1d
mAbs were purified from culture supernatants of hybridomas
grown in medium supplemented with ultra-low IgG fetal bovine
serum (Hyclone, Logan, UT) by protein G (Amersham Pharma-
cia Biotech, Inc., Piscataway, NJ) chromatography. Fluorescein-
conjugated goat anti–murine IgG antibody was obtained from
DAKO Corp. (Carpinteria, CA) and Biosource International
(Camarillo, CA).
Functional Analysis of T Cells. For activation of T cells (105/
well), anti-CD3 mAb OKT3 was bound overnight in PBS (50
ml/well) to 96-well flat-bottomed tissue culture plates, and un-
bound antibody was washed off. Coating mAb concentrations
were 1 mg/ml OKT3 for subsequent incubations with no PMA
and 0.1 mg/ml for incubations with PMA (Sigma Chemical Co.,
St. Louis, MO) at 1 ng/ml, unless otherwise indicated. Plate-
bound (50 ml/well) or soluble costimulatory mAbs at 10 mg/ml
or indicated concentrations were then added for at least 4 h. Sub-
sequently, rested T cells at 2–4 wk after PHA stimulation were
incubated with plate-bound mAb and IL-2 at 0.3 nM. In the case
of soluble mAb, an equal amount of cross-linking anti–murine
IgG antibody was added after the T cells had been allowed to set-
tle on the limiting plate-bound anti-CD3 mAb. For CD1d re-
sponses, equal numbers of CD1d1 human C1R B cell transfec-
tants or control mock-transfected C1R cells were incubated with
the rested T cells, PMA (1 ng/ml unless otherwise stated), and
IL-2 at 0.3 nM, as described previously (19).
Released cytokine levels at 48 h were determined in triplicate
by ELISA with matched antibody pairs in relation to cytokine
standards (PharMingen; Endogen, Inc., Cambridge, MA) and
converted to nanograms or picograms per milliliter using the
Softmax program (Molecular Devices Corp., Sunnyvale, CA).869 Exley et al.
Similarly, T cell proliferation between 48 and 72 h was deter-
mined by [3H]thymidine incorporation (1 mCi/well), using target
cells pretreated with mitomycin C (0.09 mg/ml) for 1 h. Results
are shown with SEM.
Cytolytic activity of Va24invt T cells was assessed by conven-
tional 51Cr-release assays as described previously (42, 43). The as-
say was performed during the T cell growth phase 7–14 d after
PHA stimulation. Spontaneous, specific, and total (Triton X-100)
51Cr released at 4 h were measured.
Assessment of Protein Interactions of NK Locus Molecules. Interac-
tion of membrane and cytosolic proteins was assessed as described
previously (44). In brief, Va24invt T cell clone DN2.B9 or the mu-
rine Va14invt TCR1 CD1d-reactive T-T hybridoma DN32.D3
was lysed with 1% Triton X-100 in Tris-buffered saline with pro-
tease inhibitors. Specific and associated proteins were precipitated
with Con A agarose beads (Amersham Pharmacia Biotech, Inc.)
or antibodies prebound to protein A/G bead mixture (Pierce
Chemical Co., Rockford, IL). After washing, bound material was
eluted under nonreducing conditions for C-type lectin Western
blotting. Protein analyzed by SDS-PAGE was blotted onto nitro-
cellulose (Schleicher & Schuell, Keene, NH) and probed with an-
tibodies. mAb HP-3G10 reacted in Western blotting with nonre-
duced CD161 (80-kD band). No activity was detected with the
reduced antigen or with other CD161 mAbs in Western blots.
p56Lck was immunoblotted with #42 serum and 3A5, followed
by second antibody–peroxidase conjugates (Promega Corp.,
Madison, WI) and chemiluminescence detection (Amersham
Pharmacia Biotech, Inc.).
Results
Potent Costimulation of Va24invt T Cells by CD161 mAb.
Human Va24invt T cells express high levels of CD161 and
variable levels of other members of the NK locus C-type
lectin family (14–20). FACSÒ profiles of two representative
Va24invt T cell clones, DN2.D5 and DN1.10B3, are
shown in Fig. 1. CD161 (NKR-P1A) was strongly ex-
pressed by these two clones derived from two different
donors (Fig. 1), as well as by all of six additional CD1d-
reactive Va24invt T cell clones (19). CD69, another C-type
lectin encoded in the NK locus, was also expressed by all of
the Va24invt T cell clones (Fig. 1; reference 19). Although
transiently expressed after activation of conventional T
cells, CD69 showed prolonged expression on Va24invt T
cell clones for at least several months after PHA stimulation
(data not shown). CD94, a third NK locus–encoded
C-type lectin, was expressed by seven out of eight Va24invt
T cell clones (not DN1.10B3; Fig. 1). Analysis of other po-
tential Va24invt T cell accessory molecules showed that p40
(45) and p38 C1.7 proteins (46), both previously found on
NK cells and some cytolytic T cells, were expressed by
some Va24invt T cell clones. However, these molecules
were also found on several control Va241 noninvariant
cells and other T cell clones not belonging to this subset
(data not shown). Va24invt T cells had variable expression
of CD28, from barely detectable on some clones to levels
comparable to conventional T cells (Fig. 1, and data not
shown). Finally, as shown previously, the Va24invt T cells
did not express the NK cell–associated p58 or p70 killer in-
hibitory receptors or the other NK cell markers CD16,
CD56, and CD57 (19). Thus, established CD1d-reactive
Va24invt T cell clones were consistently CD1611CD691,
with more variable expression of other candidate accessory
molecules.
Ligation of murine NK1 (NKR-P1C) alone activates
murine NK11 T cells and, in contrast to TCR stimulation,
results in an exclusively IFN-g–secreting Th1-biased phe-
notype (13, 39, 40). Therefore, we examined the effect of
direct ligation of CD161 on stimulation and costimulation
of human Va24invt T cells. Proliferative responses were
measured in the presence of appropriate suboptimal con-
centrations of immobilized CD3 mAb. Proliferation of all
Va24invt T cell clones tested (DN2.D5, DN2.D6, DN2.D7,
and DN1.10B3) and the Va24invt T cell line DN2.Vb111
was substantially augmented by CD161 mAbs 191.B8 (47)
and DX-1 (36) in the absence of PMA (Fig. 2 A, and data
not shown). With the addition of phorbol ester, which is
required for activation of these cells by CD1d1 targets in
vitro (19), similar costimulation by CD161 ligation was also
observed (Fig. 2 B). PMA lowered the concentrations of
CD3 mAb required z10-fold (Fig. 2, A and B). Under
both conditions, costimulation of Va24invt T cells by
CD161 was readily seen over a 25-fold range of anti-CD3
mAb concentrations (Fig. 2, A and B). Optimal costimula-
tion via plate-bound CD161 required .1 mg/ml 191.B8
coating mAb and was not seen with soluble 191.B8, even
at up to 10 mg/ml in the presence of a soluble cross-linking
secondary antibody (Fig. 2 C). In no experiment was pro-
Figure 1. Expression of NK
cell–associated proteins by
Va24invt T cells. Representative
FACSÒ analysis of DN Va24invt
T cell clones DN2.D5 (top) and
DN1.10B3 (bottom) z3 wk after
stimulation with PHA and irra-
diated feeders. T cells were
stained with mAb against the an-
tigens shown and with anti-IgG
FITC conjugate before gating on
live cells. Left to right, Normal
mouse serum (outline) and CD28
(solid line); CD69; CD94;
CD161.870 CD161 Costimulation of CD1d-specific T Cells
liferation by human Va24invt T cell clones observed in re-
sponse to plate-bound CD161 mAb in the absence of CD3
mAb (Fig. 2, A, B, and D; Table 1; and data not shown).
Similar lack of direct stimulation was observed using two
different CD161 mAbs (DX-1 and 191.B8) at concentra-
tions up to 20 mg/ml (Fig. 2, Table 1, and data not shown).
As with proliferative responses, and unlike in the mouse,
there was no IL-4 or IFN-g secretion by human Va24invt
T cell clones in response to plate-bound CD161 mAb in
the absence of CD3 mAb, either in the presence or absence
of PMA (Fig. 2 D, Table 1, and data not shown). How-
ever, both IL-4 and IFN-g production by Va24invt T cell
clones induced by limiting anti-CD3 mAb were substan-
tially augmented by CD161 mAbs 191.B8 and DX-1 in
both the presence and absence of PMA (Table 1, and data
not shown). Antibody-mediated CD161 ligation did not
alter the pattern of cytokines produced by suboptimal
TCR stimulation. IL-4 to IFN-g secretion ratios between
the CD161-costimulated and CD1d-specific responses var-
ied by only approximately threefold, and indicated that
there was no polarization of cytokine secretion toward
IFN-g production induced by CD161 costimulation of the
human Va24invt T cells (Table 1).
Similarly to CD161 mAb, CD94 mAb HP-3D9 also
produced significant costimulation of Va24invt T cell prolif-
eration (Fig. 2, A and B) and IFN-g and IL-4 secretion
Figure 2. Costimulation of Va24invt
T cells by NK locus–encoded C-type
lectins. CD1611CD941 Va24invt T cell
clone DN2.D6 (105/well, 2–4 wk after
restimulation, except where shown) was
stimulated with limiting quantities of
plate-bound CD3 mAb (OKT3 at 1 mg/
ml without PMA, or 0.1 mg/ml with
PMA at 1 ng/ml as shown) and/or
plate-bound or soluble accessory mAb
(10 mg/ml, except as shown). For solu-
ble mAb, cross-linking anti-IgG was also
added at molar equivalence. T cell pro-
liferation measured by [3H]thymidine
incorporation (cpm) was determined in
triplicate at 72 h (SEM shown). Similar results were obtained by IL-4 and IFN-g cytokine ELISA at 48 h (not shown). (A and B) Titration of anti-CD3
mAb in the presence of 10 mg/ml potential accessory molecule antibodies without (A) or with (B) PMA. (C) Titration of soluble and plate-bound
CD161 costimulatory mAb 191.B8 with 0.1 mg/ml anti-CD3 mAb and PMA. (D) 1.0 mg/ml anti-CD3 mAb and/or 10 mg/ml CD161 and/or CD94
costimulation; no PMA. (E) Partially rested T cells at only 9 d after restimulation, with 1.0 mg/ml anti-CD3 mAb, 10 mg/ml CD161 and/or CD94 co-
stimulation, and no PMA, or with PHA only.
Table 1. Comparison of Va24invt T Cell Responses to Mitogenic 
Antibody and CD1d
Stimulus Proliferation IFN-g IL-4 IL-4/IFN-g
None 8,951 ,100 ,100 —
CD3 35,077 3,320 ,100 —
CD161 6,930 ,100 ,100 —
CD3/CD161 89,525 10,670 734 0.069
CD94 8,199 ,100 ,100 —
CD3/CD94 73,020 8,963 497 0.055
CD161/CD94 9,824 ,100 ,100 —
CD3/CD161/CD94 93,072 11,250 626 0.056
C1R CD1d 27,133 41,080 916 0.022
CD1611 Va24invt T cell clone DN2.D6 (105cells/well) was stimulated
with limiting quantities of plate-bound CD3 mAb (0.1 mg/ml; 1 ng/ml
PMA) and plate-bound (10 mg/ml) accessory mAb (CD161 191.B8 or
CD94 HP-3D9) as in Figs. 2 and 3. In the same experiment, additional
DN2.D6 cells were stimulated with live CD1d1 C1R cell transfectants
(105/well; 1 ng/ml PMA) as in Fig. 4. Results shown are representative
of three independent experiments where both plate-bound and CD1d
responses were measured in parallel. [3H]Thymidine incorporation was
determined in triplicate at 72 h, shown as cpm. IL-4 and IFN-g cyto-
kine ELISA (pg/ml) were determined at 48 h. Cytokine detection limits
were ,100 pg/ml. —, Cytokine ratios not calculable due to undeter-
mined cytokine levels below detection limits.871 Exley et al.
(Table 1) in both the absence and presence of PMA.
Va24invt T cell clone DN1.10B3, which expressed CD161
but no detectable cell surface CD94 (Fig. 1 A), was
strongly costimulated by CD161 mAb, but not by CD94
mAb (not shown). However, as with CD161, there was no
direct activation of Va24invt T cell proliferation or cytokine
secretion through CD94 alone or in combination with
CD161, using several different antibodies (Fig. 2, A, B, and
D; Table 1; and data not shown). In no case was synergistic
or even additive costimulation of proliferation by CD161
and CD94 mAbs seen (Fig. 2 D, and Table 1), and in no
case was significant alteration of cytokine secretion ob-
served with simultaneous addition of both mAbs (Table 1).
This was true even at lower levels of CD3 mAb and subop-
timal levels of costimulation of proliferation by more re-
cently activated Va24invt T cells (Fig. 2 E). Anti-CD28
mAb (CD28.2), which potently costimulated control con-
ventional T cell clones (not shown), showed only weak co-
stimulation of the proliferation and cytokine secretion of
the CD281 Va24invt T cell clones, and only in the absence
of PMA (Fig. 2, A and B). Anti-p40 mAb NKTA255 was
also costimulatory for Va24invt T cells, but only in the ab-
sence of PMA (not shown). CD69 mAb (Fig. 2, A and B),
p38 C1.7 mAb (not shown), MHC class I mAb, and iso-
type-matched nonbinding control mAb had no costimula-
tory or direct stimulatory activity (Fig. 2, A and B, and data
not shown). Therefore, human Va24invt CD1d-reactive T
cells differed from their murine counterparts in lack of
direct activation in response to CD161, or indeed, other
C-type lectin ligation, whereas both CD161 and CD94
mAbs were specifically costimulatory.
Role of CD161 in CD1d-dependent Activation of Va24invt
T Cells. Since CD1d is a natural ligand of Va24invt T
cells, it was important to determine whether CD161 or
other molecules contributed to T cell activation in response
to CD1d1 target cells. Va24invt T cells were incubated with
CD1d transfectants, and proliferation and cytokine re-
sponses were measured. Recognition of CD1d1 human B
cell transfectants by Va24invt T cells, measured as prolifera-
tion, or IFN-g or IL-4 cytokine secretion, was inhibited by
CD1d mAbs 51.1 (Fig. 3, A–C) and 42.1 (not shown).
Proliferation in response to CD1d was comparably inhib-
ited with CD161 mAb DX-1 (Fig. 3 A). Similarly, secre-
tion of both IFN-g and IL-4 was inhibited by CD161 mAb
DX-1 (Fig. 3, B and C). Each of three different CD161
mAbs tested inhibited proliferative and cytokine secretion
responses to CD1d recognition, with HP-3G10 consis-
tently the most potent, followed by 191.B8, and then
DX-1 (Fig. 3, D and E, and data not shown). Inhibition of
proliferation and cytokine secretion in response to CD1d
by CD161 mAb was seen over a wide range of PMA con-
centrations (0.05–5 ng/ml; Fig. 3, and data not shown) and
not just under suboptimal conditions (,1 ng/ml PMA).
In contrast to these results with CD161 mAb, the co-
stimulatory CD94 mAb HP-3D9 did not inhibit T cell
proliferation or cytokine secretion in response to CD1d
(Fig. 3, A–C). Other mAbs specific for CD94 (DX-22 and
HP-3B1), CD69 (FN50), p38 (C1.7), and the weakly co-
stimulatory p40 mAb (NKTA255) had no consistent inhib-
itory effect on CD1d-dependent T cell proliferation or cyto-
kine secretion (not shown). The HLA class I control mAb
(W6/32) had a small inhibitory effect (Fig. 3, D and E),
Figure 3.  CD1d and CD161 mAbs specifically
inhibit Va24invt T cell response to CD1d. Va24invt
T cells (105/well) were stimulated with mitomycin
C–treated CD1d1 C1R cell transfectants (105/well)
and 1 ng/ml PMA. Control, CD1d-specific, and
other mAbs were included in incubations at 10 mg/
ml. Representative results from five independent
experiments are shown. (A) DN2.D6 T cell prolif-
eration (cpm) was determined in triplicate at 72 h.
(B) IFN-g cytokine ELISA was determined at 48 h
from the same experiment as in A. (C) IL-4 deter-
mined as for IFN-g. Control mock C1R-contain-
ing wells had background proliferation of 6,000
cpm, 6.4 ng/ml IFN-g, and 2.4 ng/ml IL-4. In a
further experiment with two Va24invt T cell clones,
three different CD161 mAbs were used. (D)
DN2.D6. (E) DN2.D5.872 CD161 Costimulation of CD1d-specific T Cells
(Fig. 4 A) and could reduce cytolysis to nearly background
levels at higher concentrations of mAb (Fig. 4, A and B).
This confirmed that cytolytic activity, like proliferation and
cytokine secretion, was a response to the intact CD1d mol-
ecule. The cytolytic activity of Va24invt T cells was abol-
ished by EGTA, indicating a Fas-independent mechanism
requiring release of cytolytic granules (Fig. 4 B).
To determine the role of CD161 in cytolytic activity,
CD161 mAbs were also included. No effects of any of the
three CD161 mAbs on CD1d-specific cytolytic activity
were seen at up to 10 mg/ml. This was true even when a
limiting amount of CD1d mAb (0.08 mg/ml) was included
to amplify any inhibition (Fig. 4 B), after preliminary ex-
periments showed no inhibition by CD161 alone. Cyto-
lytic responses were also PMA-independent. These results
demonstrated that costimulatory pathways activated by
CD161 ligation and PMA were not required for CD1d-
specific cytolytic activity of Va24invt T cells. These obser-
vations parallel conventional CTLs, for which costimula-
tory molecules such as CD28 are not required to induce
cytolysis by recently activated T cells.
Lack of Association of Va24invt T Cell p56Lck and Human
CD161. Because DN Va24invt T cells lack CD4 and
CD8ab, which are essential for physiological activation of
conventional T cells through p56Lck, an association between
Va24invt T cell p56Lck and certain accessory molecules might
be expected. Association between murine NK1 and p56Lck
has been described (48), but human CD161 (36) does not
contain the cytoplasmic tail p56Lck binding motif found in
CD4 and CD8 (49) and in all of the murine NKR-P1 mol-
ecules (1) (see Fig. 5 A). Therefore, we directly tested for
which was also seen using CD1d1 CHO cells as targets
(not shown). Since the class I mAb does not bind to cells of
hamster origin, this result appears to reflect mAb binding
directly to the T cells in the assay.
Involvement of molecules other than CD1d on the target
cell and CD161 on the T cell was tested by incubation with
mAbs against various molecules preferentially expressed on
resting and activated B and/or T cells. mAbs against CD19,
CD20, CD22, CD23, CD24, CD25, or CD28 did not affect
activation of invariant TCR1 T cells by CD1d1 B cells,
whether measured as proliferation, or IFN-g or IL-4 secre-
tion (not shown). Consistent with lack of effect of CD28
mAb, CTL-associated antigen 4 (CTLA4)–Ig fusion protein,
which blocks both B7-1 and B7-2 costimulation, had no sig-
nificant effect on CD1d-dependent T cell stimulation (S.B.
Wilson, personal communication). Therefore, of the mole-
cules studied, only CD1d itself and CD161 were found to
contribute to Va24invt T cell responses to CD1d1 target cells.
Lack of CD161 Dependence of CD1d-specific Cytolysis by
Va24invt T Cells. Recently activated Va24invt T cell clones
displayed potent and specific cytolytic activity against C1R
CD1d1 transfectants (Fig. 4). Va24invt T cell clones in-
duced 20–70% of maximal 51Cr release from CD1d1 C1R
cells at E/T ratios of 10:1 (Fig. 4 A, and data not shown).
Cytotoxicity of the same T cell clones against C1R mock
transfectants was ,10% at these E/T ratios, demonstrating
CD1d specificity of cytolysis. As seen for proliferative and
cytokine secretory responses above, the CD1d-specific cy-
tolytic effector response of the T cell clones was inhibited
in a dose-dependent manner by CD1d-specific mAbs 42.1
and 51.1. These CD1d mAbs had an IC50 of z1 mg/ml
Figure 4. Cytolytic responses
of Va24invt T cells to CD1d1
target cells. Va24invt DN2.D6 T
cells were stimulated with 51Cr-
loaded CD1d1 or mock C1R cell
transfectants. (A). E/T ratio titra-
tion. CD1d (51.1) antibody inhi-
bition of target cell lysis (1 and 10
mg/ml). (B) Antibody inhibition
of target cell lysis. CD1d (51.1) at
10 mg/ml or CD161-specific mAb
(DX-1) with 51.1 at 0.08 mg/ml
were included in incubations. 
Figure 5. Association of p56Lck with murine NK1, but not human Va24invt T cell CD161. (A) Comparison of human (reference 36) and murine
NKR-P1 (references 1 and 2) amino acid sequences around the functional p56Lck binding motif (reference 47) found in murine NKR-P1C. (B) p56Lck
immunoblot of nonreduced murine p56Lck, NK1.1, and control immunoprecipitations from Va14invt T-T hybridoma DN32.D3. (C) p56Lck immunoblot
of CD3, CD161, and Con A precipitations from Va24invt T cell clone DN2.B9. (D) CD161 (HP-3G10) immunoblot of nonreduced p56Lck, CD161
(DX-1), or control mAb (Cont.) immunoprecipitations from Va24invt T cell clone DN2.B9.873 Exley et al.
interaction of CD161 with Va24invt T cell p56Lck by immu-
noprecipitation and subsequent Western blotting.
In preliminary experiments, it was confirmed that mu-
rine NK11 T cell hybridoma DN32.D3 (7) did show asso-
ciation of NK1.1 with p56Lck (Fig. 5 B). Human p56Lck was
also expressed by DN Va24invt T cells, and Con A precipi-
tation of Triton X-100 lysates followed by Western blot
showed that p56Lck was constitutively associated with gly-
coprotein(s) (Fig. 5 C). However, CD161 immunoprecipi-
tates did not contain detectable p56Lck (Fig. 5 C). Further-
more, in the reciprocal experiment in which Triton X-100
lysates were immunoprecipitated with p56Lck antibody and
immunoblotted with CD161 mAb, there was also no de-
tectable association of CD161 with p56Lck (Fig. 5 D). We
conclude that p56Lck was not stably associated with CD161
in Va24invt T cells. Taken together, the results presented
support the model that human CD161 functions as a novel
costimulatory molecule for human Va24invt T cells.
Discussion
CD1611 Va24invt T cells are likely to play an important
immunoregulatory role (28, 31–35), presumably through
interactions with CD1d1 target cells (19). However, it is
unclear how activation and effector functions of this T cell
population in response to CD1d recognition are regulated.
By analogy with conventional MHC-restricted T cells, it
appears likely that activation of Va24invt T cells is regulated
by the engagement of accessory molecules on the T cell
surface by specific ligands expressed by appropriate target
cells. In the absence of CD4 and CD8ab and with highly
variable levels of CD28, therefore, CD161 and other re-
lated molecules were investigated as potential costimulatory
or accessory molecules for Va24invt T cells. The results re-
ported here indicate that CD161–ligand interactions posi-
tively regulate CD1611 Va24invt T cell activation.
CD161, the single known human NKR-P1 molecule,
which was first characterized on NK cells and some T cell
populations (36), is expressed at high levels by Va24invt T
cells (18–20). In contrast to results in the mouse (39), anti-
CD161 mAb did not directly activate human Va24invt T
cells. However, activation with limiting quantities of anti-
CD3 mAb revealed costimulatory activity of CD161 liga-
tion for CD1d-reactive Va24invt T cell proliferation and
cytokine secretion. Phorbol ester lowered the threshold for
CD3 activation, but did not substitute for CD161 costimu-
lation, implying that the latter activity was not solely pro-
tein kinase C–dependent. Furthermore, unlike with mu-
rine NK11 T cells, CD161 ligation did not alter the pattern
of cytokines produced by Va24invt T cells. Antibody-medi-
ated blocking showed that CD161 costimulation was nec-
essary for CD1d-dependent Va24invt T cell proliferation
and cytokine secretion, as both of these activities were spe-
cifically inhibited by all three CD161 mAbs tested. Thus, a
direct role was demonstrated for CD161 in the response of
Va24invt T cells to a physiological ligand, CD1d.
Other NK locus–encoded C-type lectin molecules, CD69
and CD94, were also expressed by most but not all (in the
case of CD94) of the Va24invt CD1d-reactive T cell clones
derived from two individual donors. CD94 expression by
Va24invt T cells appears to be variable between donors, and
may be relatively uncommon in vivo (18). The Va24invt T
cell clones in this study retained expression of CD69 up to
4 mo after stimulation. CD69 expression of freshly isolated
Va24invt T cells from several donors was low (18), and
might also be elevated by in vitro culture. Alternatively,
expression may vary between different donors, since multi-
ple independently raised Va24invt T cell clones from addi-
tional donors were also constitutively CD691 and variable
with respect to CD94 expression (S.B. Wilson, personal
communication). Conversely, another NK cell marker,
CD56, may be expressed on Va24invt T cells in situ (20),
although it is absent from the established clones we have
studied (19).
Those Va24invt T cells that expressed CD94 showed co-
stimulation with CD94 mAb. An mAb against a third re-
cently cloned molecule, p40 (45, 50), was mildly costimu-
latory in the absence of PMA for both Va24invt and control
T cells expressing this antigen. Similarly, CD28, the classic
costimulatory molecule of conventional T cells, was consis-
tently only weakly costimulatory on CD281 Va24invt T
cells in the absence of PMA, and had no detectable effect in
the presence of PMA. In contrast to the results with
CD161, neither CD94, p40, nor several other candidate
accessory molecules tested appeared central to Va24invt T
cell activation in response to CD1d. None of the three
CD94 mAbs tested had consistent effects on CD1d-depen-
dent Va24invt T cell proliferation or cytokine secretion.
CD28 mAb did not block CD1d-dependent Va24invt T
cell responses, even of those clones that expressed signifi-
cant levels of this molecule. Furthermore, CTLA4–Ig fu-
sion protein did not block CD1d-dependent T cell activa-
tion (S.B. Wilson, personal communication). However,
the requirement for PMA in the CD1d recognition assay
suggests that additional costimulatory signals must be pro-
vided concurrently with CD161 ligation for activation of
resting Va24invt T cells in response to CD1d. It is known
that human CD1b- and CD1c-restricted T cells use a
CD28-independent costimulatory pathway (51), and this
appears to be independent of CD161 (M. Exley and S.
Porcelli, unpublished observations).
The primary effector function associated with Va24invt T
cells has been production of Th1 and Th2 cytokines. Mu-
rine hepatic NK11 T cells have also been shown to have
NK-like cytolytic activity (29), but whether they can me-
diate CD1d-restricted cytolysis has not been determined.
Furthermore, murine NK11 T cells directly mediate anti-
tumor effects through a cytotoxic mechanism that appears
to be CD1d-independent (30). This report demonstrates
that an additional effector function for human Va24invt T
cells is direct CD1d-restricted cytolysis. The major mecha-
nism of this effector activity appears to be cytolytic granule
release, based on Ca21 dependence. Significantly, this ac-
tivity was PMA-independent and was not affected by
CD161 mAb. These results likely reflect the less stringent
requirements for triggering of the cytolytic effector func-874 CD161 Costimulation of CD1d-specific T Cells
tion of activated T cells than for full activation of resting
cells. The inability of CD161 mAb to block cytolytic activ-
ity provides evidence against CD161 functioning as a core-
ceptor for CD1d recognition, analogous to the role of CD4
and CD8, since CD8 mAb routinely inhibits conventional
cytolytic T cells. In contrast, this suggests a parallel with
other costimulatory molecules such as CD28, which are
not required for cytotoxic T cell lysis of target cells. Alter-
natively, the Va24invt TCR could have very high affinity
for CD1d, which can eliminate the need for coreceptor li-
gation for cytolysis, as has been described for some CD8-
independent cytolytic T cells (52).
To further assess how CD161 contributes to activation
of Va24invt T cells, association between CD161 and p56Lck
was assessed. Rodent NKR-P1C (NK1) is directly stimula-
tory for both NK cells and NK11 T cells (3, 13, 39, 40)
and can associate with p56Lck via a cytoplasmic tail motif
CXCP/S/T (47), as used by CD4 and CD8 (48). How-
ever, human CD161 does not contain this motif, and mAbs
against this molecule do not directly activate nor do they
block classical human NK cell cytolysis (36). Human
Va24invt T cell CD161 did not detectably associate with
p56Lck using detergent conditions (1% Triton X-100),
which readily confirmed the murine NK1.1–p56Lck inter-
action. Based on lack of association of human CD161 with
Va24invt T cell p56Lck, and by functional analogy with the
classical costimulatory molecule CD28, we propose that
human CD161 ligation results in activation of another sig-
naling molecule. Interestingly, the response of Va24invt T
cells to CD1d transfectants in vitro is PMA-dependent, and
CD161 can still provide a costimulatory signal in the pres-
ence of PMA, suggesting that the CD161 costimulatory
signal does not depend solely on classical protein kinase C
molecules. Murine NK1 also associates with the FcR g
chain in both NK cells and NK11 T cells (40), providing
an alternate mechanism for recruitment of signal transduc-
ing complexes. Further characterization of CD161-associ-
ated signal-transducing molecules should provide a molec-
ular mechanism for the involvement of CD161 in positive
regulation of human Va24invt T cell responses to CD1d.
The blocking of Va24invt T cell responses to CD1d1 tar-
get cells by CD161 antibodies indicates that these target
cells and their physiological CD1d1 counterparts in vivo can
express CD161 ligand(s). Although CD161 is a member of
the C-type lectin superfamily, it is not clear that carbohydrate
alone can be the ligand. As discussed above, one possible
CD161 ligand is CD1d itself. In this model, CD161 con-
tributes to CD1d recognition directly as a coreceptor (8), as
CD4 and CD8 bind MHC class II and I molecules, respec-
tively. An alternative suggested above is that human CD161
acts like CD28 and binds a true costimulatory ligand on
physiological CD1d1 target cells. CD1d on CHO cells is
insufficient to activate Va24invt T cells without mild glutar-
aldehyde fixation (19), which has been found in other
systems to artificially substitute for costimulatory signals
(51, 53). Similarly, fixation markedly increases Va24invt T
cell response to CD1d1 Hela transfectants, but not to the B
lymphoblastoid cells used in this study (M. Exley, unpub-
lished observations). Therefore, such a CD161 costimula-
tory ligand may only be expressed by certain cell types.
In summary, we have found that human CD161 functions
not as a direct stimulatory structure but as a costimulatory
molecule for human Va24invt T cell responses to their
physiological ligand, CD1d. Activation of resting CD1611
Va24invt T cells via the TCR in combination with signals
mediated by CD161 ligation led to proliferation, and both
Th1- and Th2-type cytokine secretion. However, the po-
tent granule-mediated CD1d-restricted cytotoxic activity
of preactivated Va24invt T cells was CD161-independent.
The costimulation of CD1d recognition through CD161
appears to reflect a different mechanism for activation of
human Va24invt T cells compared with rodent NK cells
and NK11 T cells, for both of which NKR-P1 is directly
stimulatory and associated with p56Lck (3, 4, 37, 38, 48).
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